Predicting Survival of Patients With Advanced Non-Small Cell Lung Cancer

Key points
- Healthcare providers have observed it for years - patients who appear to have a better quality of life while battling their cancer live longer.
- The study included patients with locally advanced non-small cell lung cancer enrolled in a treatment trial (Radiation Therapy Oncology Group 9801 assessing the addition of amifostine to induction chemotherapy followed by concurrent chemoradiation).
- "Our study shows that what matters most is what patients themselves are telling us about their quality of life", said Benjamin Movsas, M.D., principal investigator of the RTOG study and senior author of the abstract.
- Of the 239 patients analyzed, 91 percent completed a pre-treatment quality of life questionnaire.
Quality of Life is the Most Important Indicator for Predicting Survival of Patients With Advanced Non-Small Cell Lung Cancer
Healthcare providers have observed it for years - patients who appear to have a better quality of life while battling their cancer live longer. Now, a prospective, multi-institutional study examining the quality of life of patients with locally advanced non-small cell lung backs that observation. In fact, quality of life is so important, it out-weighs other classic predictors of survival.
“In the past, we’ve consider the stage of disease or tumor size along with other empirical data to predict how long a patient will survive, but now we know quality of life is a critical factor in determining survival,” said Nicos Nicolaou, M.D., an attending physician in the radiation oncology department at Fox Chase Cancer Center in Philadelphia and lead author of the abstract.
The study included patients with locally advanced non-small cell lung cancer enrolled in a treatment trial (Radiation Therapy Oncology Group 9801 assessing the addition of amifostine to induction chemotherapy followed by concurrent chemoradiation). In addition to quality of life surveys, factors used to predict overall survival, included stage of disease, gender, age, race, marital status, type of tumor, tumor location in the lung, blood oxygen level, and type of treatment.
"Our study shows that what matters most is what patients themselves are telling us about their quality of life", said Benjamin Movsas, M.D., principal investigator of the RTOG study and senior author of the abstract. Movsas is chairman of the Radiation Oncology Department at Henry Ford Hospital in Detroit.
Of the 239 patients analyzed, 91 percent completed a pre-treatment quality of life questionnaire. Patients with a quality of life score less than the median (66.7) had a 69% higher rate of death than patients with a quality of life score greater than 66.7 (p=0.002).
“We conducted two different statistical analysis including all the usual prognostic factors and either way, quality of life remained the strongest predictor of overall survival. What’s more, if a patient’s quality of life increased over time, we saw a corresponding increase in survival,” Movsas said.
Married patients or those with a partner had the highest quality of life score.
“We found a significantly lower quality of life score for single, divorced and widowed patients which deserves further study,” Nicolaou said. “These findings underscore the importance of helping our patients improve the quality of life where we can in order to help them live longer better.”
“Quality of life measures should be incorporated into treatment decision making and clinical trials,” Movsas concluded.
The results of the study were presented today at the American Society for Therapeutic Radiology and Oncology’s 49th Annual Meeting in Los Angeles.
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsCT and serum LDH shows promise as survival predictor for some metastatic melanoma patients
Combining CT imaging findings with baseline serum lactate dehydrogenase levels is showing promise as a way to predict survival in patients with metastatic melanoma being treated with anti-angiogenic therapy. With the…
18 April 2013
NewsOveractive Marker May Shorten Survival of Brain Tumor Patients
Researchers may have discovered a more accurate way to predict how long patients with the deadliest form of brain cancer will live, according to an analysis by researchers from the University of Alabama at Birmingham…
11 April 2013
NewsPET/CT Shows Clear Advantages over Conventional Staging for Patients with Locally Advanced Breast Cancer
New research published in the January issue of The Journal of Nuclear Medicine shows that 18F-fludeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) imaging offers significant prognostic…







